Skip to main content
. 2016 May 23;60(6):3283–3290. doi: 10.1128/AAC.01916-15

FIG 5.

FIG 5

In vivo efficacy test of three novel compounds, molucidin, ML-2-3, and ML-F52. (A) Parasitemia changes for 20 days postinfection. Five consecutive daily shots of 30 mg/kg of each compound were inoculated (intraperitoneally) as well as vehicle-treated mice (Neg Control). ML-F52-treated mice showed no parasitemia for 20 days. (B) Survival rate curve for 20 days postinfection. ML-F52-treated group showed 100% cure for 20 days postinfection.